BIOCORP
17.2.2021 08:02:10 CET | Business Wire | Press release
Regulatory News:
BIOCORP (FR0012788065 - ALCOR / Eligible PEA PME) (Paris:ALCOR), a French company specialized in the design, development and manufacturing of innovative medical devices, today announces the signature of new partnerships with Health2Sync and SocialDiabetes, companies headquartered in Taiwan and Spain, respectively.
These two partnerships involve the integration of Mallya, the connected device dedicated to insulin pens, with the digital applications developed by Health2Sync and SocialDiabetes to improve the quality of care for patients with diabetes.
In detail, the platform developed by SocialDiabetes (CE marked and FDA 510K) allows self-monitoring of insulin doses and offers personalized recommendations to patients. All of the data collected feeds a telemedicine platform using augmented intelligence for physicians and specialized call centers. To date, this platform is used by 250,000 patients with diabetes, mainly in Spain, Mexico, Colombia and Chile.
Health2Sync’s app, through its analytics engine, provides personalized recommendations and nudges concerning meals, exercise, and blood glucose management, delivered in a compelling way that encourages users to stay adherent to treatment plans. Health2Sync’s Patient Management Platform utilizes decision support modules for healthcare providers to deliver effective interventions that are also scalable, with insulin dosing as an example. The patient management platform is deployed in over 260 of diabetes care institutions in Taiwan, Malaysia and Japan, and the mobile app is used by more than 600,000 patients in Taiwan, Japan, USA, Hong Kong, Malaysia, Singapore and Australia.
Patients using these digital solutions will be able to automatically synchronize the data recorded by their Mallya sensor, thus benefiting from a complete monitoring offer combining glycemic data analysis and insulin dose feedback. This information can be transmitted in real time to treating physicians via a devoted portal to improve the quality of dialogue with patients, optimize treatment plans and offer personalized recommendations.
Éric Dessertenne, CEO of BIOCORP, explained: “These new partnerships come at a time when our teams are preparing for the large-scale commercial launch of Mallya, which is already compatible with almost all disposable pens on the market. Its integration with the most widely used applications in local markets is a great advantage for the rapid adoption of Mallya in these countries. Health2Sync and SocialDiabetes will enable us to accelerate our penetration in Asia and some Latin American countries, geographical areas where the diabetic population and the use of connected medicine are highly developed".
”Health2Sync bridges the lengthy gap between doctor visits by enabling frequent digital touch points between patients and healthcare providers. Insulin dosing data captured by Mallya will significantly enhance the experience of patients on insulin “said Ed Deng, Co-Founder and CEO of Health2Sync. “We expect better adherence and improved outcomes that come as a result of making data available to patients and healthcare providers .”
“We are thrilled to initiate this agreement with Biocorp. Mallya sensor is a world-class player and represents the type of high-quality technology we want to bring to our customers. Patients increasingly demand combined solutions that provide them with high connectivity and data driven personalized support. This alliance with Biocorp is a big step toward the digital health ecosystem the market is waiting for . “said María Jesús Salido, cofounder & CEO of Social Diabetes.
ABOUT HEALTH2SYNC
Founded in 2013, Health2Sync provides a comprehensive health-management platform for people with chronic conditions. Its products combine mobile, cloud, and data analytics, enabling patients to obtain personalized care and allows care providers and family to care for patients remotely. With the largest network of clinics and hospitals, it is the leading solution in Asia that brings an effective, yet scalable solution to diabetes management.
For more information, please visit https://www.health2sync.com
ABOUT SOCIAL DIABETES
SocialDiabetes is set to become one of the best solutions to foster the digital management of diabetes. Leader in Spanish speaking markets, the company, headquartered in Barcelona with offices in the UK, and Ciudad de Mexico was first created to meet the needs of Victor Bautista, a Type 1 diabetes patient and current CTO & co-founder. A company of patients working for patients, SocialDiabetes provides a system that synchronizes with multiple devices, easily connect patients with the healthcare professionals that are treating them and provides relevant information for decision making in one place.
For more information, please visit www.socialdiabetes.com
ABOUT BIOCORP
Recognized for its expertise in the development and manufacture of medical devices and delivery systems, BIOCORP has today acquired a leading position in the connected medical device market thanks to Mallya. This smart sensor for insulin injection pens allows reliable monitoring of injected doses and thus offers better compliance in the treatment of patients with diabetes. Available for sale from 2020, Mallya spearheads BIOCORP's product portfolio of innovative connected solutions. The company has 70 employees.
BIOCORP is listed on Euronext since July 2015 (FR0012788065 – ALCOR).
For more information, please visit www.biocorpsys.com
.
View source version on businesswire.com: https://www.businesswire.com/news/home/20210216005923/en/
Link:
About Business Wire
Subscribe to releases from Business Wire
Subscribe to all the latest releases from Business Wire by registering your e-mail address below. You can unsubscribe at any time.
Latest releases from Business Wire
Suzano 2025 Annual Report on Form 20-F28.4.2026 23:32:00 CEST | Press release
Suzano S.A. (B3: SUZB3 | NYSE: SUZ) informs that its 2025 Annual Report on Form 20-F was filed on March 24, 2026 with the U.S. Securities and Exchange Commission. Holders of the Company’s equity securities can receive hard copies of the Annual Report, including its audited financial statements, without charge by request directed to: ri@suzano.com.br. This document is also available on Suzano’s website (http://ir.suzano.com.br/). For further information, please contact our Investor Relations Department: Phone: (+55 11) 3503-9330 E-mail: ri@suzano.com.br View source version on businesswire.com: https://www.businesswire.com/news/home/20260428152792/en/
Laserfiche Introduces AI Agents: The Future of Intelligent Content Management28.4.2026 23:00:00 CEST | Press release
New agentic AI capabilities allow any user to automate intelligent, multi-step workflows using natural language. Today at the Laserfiche Empower conference — the premier event for intelligent content management —Laserfiche announced the release of AI Agents. With simple, natural language prompts, these virtual assistants perform complex, multi-step tasks and work within the framework of Laserfiche’s robust security and compliance controls, transforming how you interact with your organization’s information. This press release features multimedia. View the full release here: https://www.businesswire.com/news/home/20260428506937/en/ Laserfiche AI Agents leverage advanced generative AI reasoning models to perform tasks that bridge the gap between building workflows and time-consuming manual effort. They can take actions based on document data and execute bulk changes from natural language user instructions. “The introduction of AI Agents to content management signals a shift in how we hand
BTG Pactual Timberland Investment Group Raises US$1.24 Billion for Largest Reforestation Fund to Date[1]28.4.2026 17:00:00 CEST | Press release
Milestone positions Latin American reforestation strategy as a leading model for scalable, high-integrity conservation and restoration—combining sustainable commercial reforestation with large-scale ecosystem conservation and restoration to target economic returns, climate and biodiversity gains, and rural community benefits. Conservation International serves as Impact Adviser for social and environmental outcomes. BTG Pactual Timberland Investment Group (BTG Pactual TIG), one of the world’s largest timberland managers, today announced the close of fundraising for its Latin American Reforestation Strategy, reaching US$1.24 billion in commitments. This represents the largest reforestation fund closed to date,1 providing a model for large-scale reforestation and restoration that seeks to deliver durable climate impact, tangible benefits for rural communities, biodiversity outcomes, and sustainable commercial production. Global environmental organization Conservation International serves
Qatar Implements Relief Measures to Support Business Community28.4.2026 16:56:00 CEST | Press release
Qatar has activated a comprehensive package of support measures designed to maintain market stability and reinforce investor confidence amid evolving regional conditions. These measures, delivered through the nation’s foreign direct investment ecosystem, provide immediate financial, regulatory and operational relief to Qatar’s international business community. This press release features multimedia. View the full release here: https://www.businesswire.com/news/home/20260428904909/en/ Infographic highlights key relief measures implemented in Qatar to support the business community (Infographic: AETOSWire) H.E. Sheikh Faisal bin Thani Al Thani, Minister of Commerce and Industry and Chairman of Invest Qatar, stated: “Qatar’s commitment to its business community is unwavering. As regional conditions continue to evolve, we remain fully focused on acting decisively to support companies operating in our market, safeguard business continuity and reinforce confidence. Our approach is grounded i
Dubai’s Medcare Hospital Becomes the World’s First to Treat an Adult Spinal Muscular Atrophy (SMA) Patient Outside the US28.4.2026 15:57:00 CEST | Press release
Medcare Royal Speciality Hospital (MRSH) in Dubai has become the world’s first hospital outside the USA, to offer a newly licensed intrathecal gene therapy - Itvisma, to adult patients with Spinal Muscular Atrophy (SMA). This one-time treatment was recently administered to a 22-year-old Egyptian patient, who was diagnosed at 18 months and confined to a wheelchair for most of his life. This press release features multimedia. View the full release here: https://www.businesswire.com/news/home/20260428038416/en/ Dr. Vivek Mundada with Medcare multidisciplinary medical team (Photo: AETOSWire) Last year, Medcare also became the first healthcare provider globally to administer the newly licensed Itvisma to a four-year-old international SMA patient. SMA is a rare neuromuscular disease that leads to progressive muscle weakness and loss of mobility, impacting movement, breathing, and swallowing. Until now, advancements in gene therapy for SMA were primarily restricted to children under the age o
In our pressroom you can read all our latest releases, find our press contacts, images, documents and other relevant information about us.
Visit our pressroom